Louis Garguilo

ARTICLES BY LOUIS

  • 4/3/2025

    A Takeda production site in Linz, Austria, received an ISPE’s 2024 Facility of The Year Award. What’s so special about that location? The explanation from Roland Fabris, Site Head, will actually help you benchmark your CDMO, and demonstrate much about facility selection applicable to your own outsourcing needs. 

  • 3/17/2025

    Tony Sampognaro of Stoke Therapeutics, says, “We're having to rearrange and bolster the constellation of CDMOs we're working with." The nice thing is, Stoke has a comprehensive extended enterprise model. Nonetheless, an all-outsourced model “can add hidden complexity." Here's how to manage that.

  • 3/14/2025

    We need a flexible hiring marketplace – a new ecosystem – to generate increased awareness by professionals and students of positions in the biopharma industry. “It’s no longer about simply posting full-time jobs,” says Chris Frew, Founder/CEO of BioBuzz Networks. But is "fractional hiring" the answer?

  • 3/3/2025

    After our "Biotech Winter" – a period starting circa 2021 with tens of thousands of layoffs and stagnating investment — is it springtime for biotech? Chris Frew, Founder/CEO of BioBuzz Networks, says yes. “We have demonstrably entered a turning point in biotech hiring.”

  • 2/24/2025

    Are we on the same page? Do we need to be? That is, how do we differ on what might seem like the mundane defining of CDMOs as small, medium, or large? Some readers have been asking. How might this determination be relative and important to individual sponsors? Our Advisory Board members weigh in.

  • 2/20/2025

    Facility investments by CDMOs continue to be magnetized to Asia. Recent examples abound. Chief Editor Louis Garguilo details some of those, and discusses whether, for example, a President Trump-intensified focus on increasing manufacturing in the U.S. can change this. Will your outsourcing in 2025 change direction? The answer may surprise you.

  • 2/17/2025

    Robert Discordia, Co-Founder, President and CEO, EQUULUS Therapeutics, knows that to advance early-stage development assets most economically, biotechs should (a) stay within their virtual model, and (b) base that outsourcing strategy on initial business objectives. Here are his dos and don'ts.

  • 2/10/2025

    An assortment of conversations with experienced biopharma executives have generated some surprising commentary about CDMO selection. Chief Editor Louis Garguilo puts those insights together in this editorial. They include selection preparation/responsibilities, and some interesting CDMO behaviors of late.

  • 2/6/2025

    Regulatory-CMC is the denominator through the career of Sai Prathyusha Bhamidipati, currently at Moderna. Regulatory-CMC focuses on ensuring compliance with regulations regarding the production and quality control of your pharmaceutical products. Bhamidipati explains the importance for the practice of which when dealing with CDMOs.

  • 2/3/2025

    Professionals in our development and manufacturing outsourcing ecosystem are worried about inadequate training – in-house at their biotechs, and at their CDMOs. A main concern is a lack of sufficiently trained personnel to perform the various technology transfers to keep our industry running efficiently.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.